Ignite Creation Date:
2025-12-24 @ 4:44 PM
Ignite Modification Date:
2026-01-06 @ 5:34 AM
Study NCT ID:
NCT07244666
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-11-24
First Post:
2025-11-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Organization:
Study Overview
Official Title:
Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Study of Metabolically Armed EGFRvII CAR-T Cells Therapy for Patients With Recurrent Glioblastoma
Detailed Description:
1. Primary Objective
Evaluate the safety and efficacy of metabolically armed EGFRvIII CAR-T cell injection in patients with recurrent glioblastoma.
2. Secondary Objectives
Evaluate the pharmacokinetics/pharmacodynamic characteristics of metabolically armed EGFRvIII CAR-T cells in patients with recurrent glioblastoma and the persistence of the CAR-T cells in the subjects.
Evaluate the safety and efficacy of metabolically armed EGFRvIII CAR-T cell injection in patients with recurrent glioblastoma.
2. Secondary Objectives
Evaluate the pharmacokinetics/pharmacodynamic characteristics of metabolically armed EGFRvIII CAR-T cells in patients with recurrent glioblastoma and the persistence of the CAR-T cells in the subjects.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: